Investors focused on the Medical space have likely heard of Editas Medicine (EDIT - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Editas Medicine is a member of the Medical sector. This group includes 762 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. EDIT is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for EDIT's full-year earnings has moved 10.32% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, EDIT has moved about 20.37% on a year-to-date basis. In comparison, Medical companies have returned an average of 0.73%. This means that Editas Medicine is outperforming the sector as a whole this year.
To break things down more, EDIT belongs to the Medical - Biomedical and Genetics industry, a group that includes 281 individual companies and currently sits at #161 in the Zacks Industry Rank. Stocks in this group have lost about 3.32% so far this year, so EDIT is performing better this group in terms of year-to-date returns.
EDIT will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Editas Medicine (EDIT - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Editas Medicine is a member of the Medical sector. This group includes 762 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. EDIT is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for EDIT's full-year earnings has moved 10.32% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, EDIT has moved about 20.37% on a year-to-date basis. In comparison, Medical companies have returned an average of 0.73%. This means that Editas Medicine is outperforming the sector as a whole this year.
To break things down more, EDIT belongs to the Medical - Biomedical and Genetics industry, a group that includes 281 individual companies and currently sits at #161 in the Zacks Industry Rank. Stocks in this group have lost about 3.32% so far this year, so EDIT is performing better this group in terms of year-to-date returns.
EDIT will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on EDIT - FREE